AP
CNCR

Atwood & Palmer’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Atwood & Palmer’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-665
Closed -$20K – 423
2021
Q1 		$20K Hold
665
– – ﹤0.01% 294
2020
Q4 		$21K Buy
+665
New +$19.9K ﹤0.01% 272

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
LWPC
Legacy Wealth Partners (California) Calabasas, California $180M AUM 48.85% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Atwood & Palmer's CNCR Position: Q2 2021 in Review

Atwood & Palmer sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2021, closing a stake of 665 shares — an estimated $20K sold.

Atwood & Palmer first reported a position in CNCR in Q4 2020 and held it in 2 quarters. The position peaked at $21K in Q4 2020. 21 funds tracked by Wall St. Rank hold CNCR as of Q2 2021.

  • Atwood & Palmer reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2021 after selling out during the quarter.
  • Atwood & Palmer sold 665 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2021, an estimated $20K.
  • Atwood & Palmer first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2020 and held it in 2 quarters.
  • Atwood & Palmer's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $21K in Q4 2020.
  • 21 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2021.

Based on Atwood & Palmer's 13F filing for Q2 2021, filed 26 Jul 2021.